Biomedical Core: Cellular and molecular mediators of fibrosis in the development of urinary tract dysfunction

生物医学核心：尿路功能障碍发展过程中纤维化的细胞和分子介质

基本信息

批准号：
10022321
负责人：
Dale Edmond Bjorling
金额：
$ 9.42万
依托单位：
UNIVERSITY OF WISCONSIN-MADISON
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-24 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10022321
关键词：
Affect Area Benign Benign Prostatic Hypertrophy Biomedical Research Bladder Caring Clinical Collaborations Communities Comparative Study Consensus Data Data Analyses Development Disease Evaluation Event Fee-for-Service Plans Fibrosis Functional disorder Funding Opportunities Future Goals Impairment Inflammation Institution Instruction Lead Lower urinary tract Mediator of activation protein Medical Methods Modeling Molecular Mus Paper Patient Care Patients Prevention Procedures Prostate Prostatic Protocols documentation Publications Quality Control Regulation Reporting Reproducibility Research Research Personnel Research Support Resources Rodent SECTM1 gene Schedule Services Signal Transduction Structure System Techniques Testing Tissues Training United States National Institutes of Health Universities Urinary tract Urine Urology Validation Washington Wisconsin Work authority clinical application genetic manipulation improved lower urinary tract symptoms medical attention meetings men mouse model programs software development testing services urinary web site

项目摘要

PROJECT SUMMARY – BIOMEDICAL RESEARCH CORE The Biomedical Research Core has three primary objectives: to analyze lower urinary function in mice in support of the three projects of the U54 O’Brien Center; to engage and collaborate with investigators to make these services generally available to the urology research community; and to refine and validate current and new techniques for evaluation of lower urinary tract function in mice. The overarching goal of the O’Brien Center for Benign Urology Research is to identify mechanisms that result in lower urinary tract dysfunction in patients with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). A primary focus of the Center is development of fibrosis in the prostate during the progression of BPH/LUTS and how altered function associated with fibrosis result in LUTS. However, patients do not pursue treatment for changes in the structure of their prostates but rather require treatment for improvement of LUTS. Thus, improved patient care can only be achieved by prevention or treatment of mechanistic events that lead to lower urinary tract dysfunction (LUTS). It is therefore vital that the effects of mechanistic changes identified in mouse models of BPH/LUTS be rigorously correlated with changes in lower urinary tract function. Results of these studies are crucial to identification of management strategies that should be considered for advancement to clinical application. Consolidation of lower urinary function testing into the Biomedical Research Core allows optimal quality control in testing, refinement of testing procedures, and development and validation of new techniques for testing lower urinary tract function in mice. The Biomedical Research Core will provide rigorous, reproducible testing of lower urinary tract function in mice for the three projects of the Center, as well as supporting needs of K12 KURe scholars in this area. The resources and expertise of the Biomedical Research Core are also available to the urology research community in general. The Biomedical Research Core has established multiple productive collaborations with external investigators, and it is anticipated that these will continue and expand in the future. Collaboration with Dr. Jianghui Hou at Washington University, St. Louis has evolved into an NIH R01 application for which Dr. Bjorling is the lead PI and Dr. Hou is the co-PI that received a highly competitive priority score (11th percentile; R01DK118145, Regulation of bladder structure and function by microRN29; Council meeting scheduled for May 5, 2019). The Biomedical Research Core will also work to establish and validate new methods of lower urinary tract function in mice and to make these techniques available to the larger research community. Thus, the Biomedical Research Core will not only provide testing service but will also act as a nidus for improvement and increased availability of techniques for evaluation of lower urinary tract function in mice.

项目摘要——生物医学研究核心生物医学研究核心有三个主要目标：分析小鼠的较低泌尿功能以支持 U54 奥布莱恩中心的三个项目中与研究人员进行接触和合作以实现这些项目的泌尿学研究界普遍可获得的服务；并完善和验证当前和新的服务；评估小鼠下尿路功能的技术奥布莱恩中心的总体目标。良性泌尿外科研究旨在确定导致患者下尿路功能障碍的机制该中心的主要关注点是良性前列腺增生（BPH）和下尿路症状（LUTS）。 BPH/LUTS 进展期间前列腺纤维化的发展以及功能改变如何相关纤维化导致 LUTS 然而，患者不会因改变其结构而寻求治疗。前列腺癌，而是需要治疗来改善 LUTS，因此，只能改善患者护理。通过预防或治疗导致下尿路功能障碍（LUTS）的机械事件来实现。因此，严格研究 BPH/LUTS 小鼠模型中确定的机制变化的影响至关重要。与下尿路功能变化相关的这些研究结果对于识别至关重要。应该考虑推进临床应用的管理策略。将泌尿功能测试纳入生物医学研究核心，可以在测试、改进过程中实现最佳质量控制测试程序，以及测试下尿路功能新技术的开发和验证生物医学研究核心将为小鼠下尿路功能提供严格、可重复的测试。该中心的三个项目的小鼠，以及支持 K12 KURe 学者在该领域的需求。生物医学研究核心的资源和专业知识也可供泌尿学研究界使用总体而言，生物医学研究核心与外部建立了多种富有成效的合作。研究人员，预计这些将在未来继续并扩大与博士的合作。圣路易斯华盛顿大学的 Jianghui Hou 已发展成为 NIH R01 申请，Bjorling 博士负责是首席 PI，侯博士是联合 PI，获得了极具竞争力的优先分数（第 11 个百分点； R01DK118145，microRN29 调节膀胱结构和功能；理事会会议定于 5 月举行； 2019 年 5 月 5 日）。生物医学研究核心还将致力于建立和验证降低尿路的新方法。小鼠的肠道功能，并使这些技术可供更大的研究界使用。生物医学研究核心不仅提供检测服务，还将作为改进和改进的巢穴。增加了评估小鼠下尿路功能的技术的可用性。